Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05968768 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 1 entry Show 4 more changesShow less
    • Secondary endpoints: details revised at 1 of 4 entries
    • Publications: details revised at 7 of 7 entries
    • Eligibility criteria expanded, about 1 word
    • Study description expanded, about 5 words
  2. 2 versions Re-verified since Apr 9, 2025, no change to tracked fieldsv4-v5
  3. Study sites: 1 to 2v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 10, 2023 to Oct 24, 2023
    • Site details revised
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Anna Raciborska
5 trials monitored
See all monitored trials
Sarcoma
1,026 trials monitored
See 67 trials at risk
Prospective, interventional, open, randomized, national, multicenter, non-commercial trial
Trial Details
NCT Number NCT05968768
Lead Sponsor Anna Raciborska
Collaborators: Wroclaw Medical University
Conditions
(from sponsor)		 Ewing Sarcoma
Related terms Sarcoma, Ewing
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov